BOULDER, CO--(Marketwired - May 1, 2015) - Peak Pharmaceuticals, Inc. (OTCQB: PKPH) ("Peak Pharma" or the "Company"), and Canna-Pet, a leading innovator of non-prescription hemp based cannabinoid products for animals, are delighted to announce that MaxCBD Maple Bacon Biscuits for dogs are once again available at its online store at www.canna-pet.com.
The Company believes the enthusiasm and strong sales during April's trial launch show a market demand for higher CBD content products. The MaxCBD Canna-Biscuits offer up to six times the CBD content of the Company's standard Canna-Biscuit product line and caters to consumers seeking the highest CBD and cannabinoid content for their dogs.
Formulated with Canna-Pet® to deliver the entire cannabinoid profile of hemp (including CBD), the biscuits are an appropriate supplement for all breeds. The product is made in the USA, with 100% organic, non-GMO, human grade food ingredients. MaxCBD Maple Bacon Canna-Biscuits are ready for use right out of the box at home or on the go.
Canna-Pet was one the first companies to discover that some animals thrive on hemp supplementation. The Canna-Pet® supplements are made with hemp plant extract, using a proprietary manufacturing process designed to yield products that mimic as closely as possible the phytochemical profile of the hemp plant. The hemp plant is a member of the cannabis family, and produces CBD among many cannabinoids, but contains only trace amounts of the psychoactive compound THC. The fact that the Canna-Pet® product lineup is based on hemp and virtually devoid of THC differentiates these products from those made from "marijuana" or "pot."
"There are both regulatory and safety concerns associated with using THC containing or 'marijuana' based products for animals, and it can be confusing when our hemp supplements are described alongside 'marijuana' based products under headlines such as 'Pot for Pets,'" says Company CEO Dr. Soren Mogelsvang. "Canna-Pet is one of the very few pet products that contains CBD from hemp, and the product lineup differs from its competitors through the use of proprietary ratios of hemp-derived cannabinoids and terpenes."
Peak Pharma invested in the animal sector in order to start commercial activities focused on the benefits of hemp supplementation as opposed to becoming mired in the complications common in the medical marijuana sector. The pet industry offers the Company a strategic, revenue generating springboard to move forward towards the development of hemp-based products for humans. Given that cannabinoids and terpenes are readily and abundantly available in hemp, the Company is intentionally steering away from THC containing marijuana products and the regulatory challenges associated with the medical marijuana industry. Consumers increasingly educate themselves through online research on the potential benefits of hemp-based cannabinoids and CBD, and this information continues to become increasingly mainstream and is propelling the execution of the Company's strategy and growth plans.
"Launching a new product is exciting. Achieving immediate sales and feedback beyond our expectations is outright thrilling," continues Dr. Mogelsvang. "The response to our MaxCBD Canna-Biscuits was so positive we immediately decided to add it to our product lineup. So today's announcement is really great news as our team worked hard to deliver adequate inventory in very short order. So far, we only offer our most popular Maple Bacon flavor in the MaxCBD serving size, but we hope to hear from our customers as to which flavor we should roll out next. We intend to create a few more flavors and based on the overwhelmingly positive customer response, we are already discussing additional product ideas in the MaxCBD category. We invite everyone to sign up for our website newsletter in order to keep informed."
About Peak Pharmaceuticals, Inc. (OTCQB: PKPH)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based supplement products for the human and animal health markets. The company aims to become a global leader in the hemp supplement industry. For more information visit www.peakpharma.com and follow us on Facebook, Twitter and LinkedIn.
About Canna-Pet® Products for Pet Health
Canna-Pet® offers non-prescription CBD products for domesticated animals such as cats and dogs. Canna-Pet® is the culmination of years of research and development to provide the benefits of hemp-based CBD and cannabinoids without the "high" typically associated with psychoactive cannabis products. The company uses non-GMO hemp as starting material and all products are proudly manufactured in the USA. In addition to CBD, Canna-Pet products differ from its competitors through the use of proprietary ratios of hemp derived cannabinoids and terpenes. Canna-Pet® is a trademarked, leading producer of safe, hemp-based, cannabidiol (CBD) containing products, which are available under an exclusive commercial license agreement with Peak Pharmaceuticals, Inc. (OTCQB: PKPH). Order online at: www.canna-pet.com or under "Pet Supplies" on Amazon, and join us on Facebook and Twitter.
Additional details of Peak Pharmaceuticals business, finances, appointments, risks and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov. For more information please visit www.peakpharma.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the U.S. Food and Drug Administration (USFDA). The products mentioned herein are not intended for human consumption, or to diagnose, treat, cure, or prevent any disease. Information contained or made available through the Canna-Pet™ website or affiliate sites is not intended to constitute or substitute for legal or veterinary advice.